OraSure Q2 revenue rises on higher diagnostics sales

OraSure Technologies

05/08/2026 21:54

Overview
US diagnostic test maker's Q2 revenue fell 2% yr/yr, core business revenue flat
Diagnostics revenue grew 1% yr/yr, driven by higher syphilis and Sickle SCAN sales
Company repurchased $2 mln in stock during Q2, totaling $22 mln under authorization

Outlook
OraSure Technologies guides Q3 2026 revenue at $29.5 mln to $32.5 mln

Result Drivers
DIAGNOSTICS SALES - Co said diagnostics revenue grew 1% yr/yr due to higher syphilis test sales and addition of Sickle SCAN sales
GROSS MARGIN IMPROVEMENT - Co reported improved gross margin in Q2, up to 43.5% from 42.1% yr/yr
INNOVATION MILESTONES - Co highlighted FDA clearance for Colli-Pee Dx urine collection device and EUA for OraQuick Ebola 2.0 Rapid Antigen Test

Company press release: ID:nGNX2f3BzC

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$30.60 mln
$29.06 mln (1 Analyst)
Q2 Gross Margin
 
43.50%
 
Q2 Adjusted Operating Income
Beat
-$14.70 mln
-$19.76 mln (1 Analyst)
Q2 Operating Income
 
$5.40 mln
 

Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for OraSure Technologies Inc is $4.00, about 4.1% below its August 4 closing price of $4.17

Reuters Recommended Reads
Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Aug 3 - GeneDx Q2 revenue beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)